BioCentury | Sep 29, 2017
Company News

Pfizer, MD Anderson partner for cancer combo clinical trials

...will evaluate combinations of Pfizer therapies plus radiotherapy, including PD-L1 mAb Bavencio avelumab, utomilumab (PF-05082566), PF-04518600...
...mAb agonist of tumor necrosis factor (TNF) receptor superfamily member 9 (4-1BB; TNFRSF9 ; CD137); PF-04518600...
...University of Texas MD Anderson Cancer Center , Houston, Texas Business: Cancer Elizabeth S. Eaton 4-1BB agonist Bavencio gemtuzumab ozogamicin glasdegib PF-04518600 Utomilumab Pfizer...
BioCentury | May 23, 2016
Clinical News

PF-8600: Phase I data

...of a 2-part, open-label, U.S. and Dutch Phase I trial showed that 0.01-0.3 mg/kg IV PF-8600...
...the head and neck (SCCHN), renal cell carcinoma (RCC) or hepatocellular carcinoma (HCC) to receive PF-8600...
...9 ( TNFRSF9 ; 4-1BB; CD137). Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: PF-8600 , PF-04518600...
BioCentury | May 19, 2016
Clinical News

New efficacy data for Pfizer's 4-1BB, OX40 programs

...of next-generation immuno-oncology programs from Pfizer Inc. (NYSE:PFE). The antibodies, PF-5082566 ( PF-2566 ) and PF-04518600...
...TNFRSF9 ; 4-1BB; CD137). It was developed using HuCAL technology from MorphoSys AG (Xetra:MOR; Pink:MPSYF). PF-04518600...
...lung cancer (NSCLC), head and neck cancer and thyroid cancer. The first human data for PF-04518600...
BioCentury | Nov 9, 2015
Strategy

Pfizer's growth spurt

...a human HuCAL mAb agonist of tumor necrosis factor (TNF) receptor superfamily member 9 (4-1BB); PF-04518600...
Items per page:
1 - 4 of 4